Cel­sius aims to cool down in­flam­ma­tion with new in­vestors and more phar­ma deals

Broad In­sti­tute spin­out Cel­sius Ther­a­peu­tics is turn­ing up the heat on the fi­nanc­ing front as it looks to ice the symp­toms of in­flam­ma­to­ry bow­el dis­ease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER